Ask ten healthcare providers about peptide therapies, and you’re likely to get ten different answers.

Some see peptides as one of the most promising developments in regenerative and longevity medicine. Others are more cautious, pointing to the evolving science and uncertain regulatory landscape. Most fall somewhere in between – interested in the potential, but mindful that many questions remain unanswered.

What is clear, however, is that peptide therapies are no longer a niche topic. They are being discussed across primary care offices, wellness practices, med spas, and longevity-focused practices. Patients are also arriving with more questions than ever after reading about peptides on social media or discussing them in fitness and wellness communities.

As this interest continues to grow, regulatory attention is following.

The FDArecently released briefing materials ahead of the July 23–24, 2026 meeting of the Pharmacy Compounding Advisory Committee, where the Committee evaluated several peptide substances nominated for use in compounded medications, including BPC-157, KPV, TB-500, and MOTS-C. While the discussion is technical, the practical significance is straightforward: the FDA is taking a closer look at whether the available scientific evidence supports the use of certain peptides in this context, and whether they belong on the list of bulk substances that may be used in traditional pharmacy compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act.

Why This Matters Beyond Compounding Pharmacies

Although the formal regulatory process relates to compounded medications, the implications extend well beyond compounding pharmacies.

Physicians, nurse practitioners, physician assistants, med spas, wellness clinics, and longevity practices are increasingly involved in discussing or offering peptide therapies. In that environment, FDA assessments often function as an important reference point for how regulators view the current strength of the evidence supporting particular substances.

Even when a therapy is widely discussed or commercially available, that does not necessarily mean its safety profile, effectiveness, or appropriate clinical use is firmly established in the medical literature. As interest grows faster than the evidence base in some areas, providers are often left navigating that gap in real time.

Where Compliance Issues Typically Arise

For healthcare providers, regulatory risk in this area is usually not about whether a therapy exists or is offered. It tends to arise in how it is presented and documented:

• Marketing and Advertising: Website content and promotional materials sometimes describe peptide therapies in terms of outcomes such as accelerated recovery, weight loss, improved cognition, or anti-aging effects. These types of claims should be carefully evaluated against the strength of the supporting evidence.

• Patient Expectations: Patients often arrive with pre-formed expectations based on social media, podcasts, or informal recommendations. It is important that clinical discussions accurately reflect both the potential benefits and the limitations of current evidence.

• Informed Consent: Consent documents should clearly communicate known risks, as well as any areas where clinical data remains limited or evolving.

• Consistency Across Communications: Regulators often look at whether marketing materials, clinical discussions, and medical records tell a consistent story. Misalignment between those sources can create unnecessary exposure.

Looking Ahead

The FDA’s review does not represent a final determination on the future of peptide therapies. It is part of an ongoing process that will continue to evolve as additional scientific data becomes available and regulatory priorities develop.

At a broader level, the situation highlights a recurring theme in modern healthcare: innovation frequently moves faster than formal regulatory consensus. That gap does not require providers to avoid emerging therapies, but it does require careful attention to how those therapies are described, documented, and integrated into practice.

Practices that periodically review their marketing language, informed consent processes, and clinical protocols are better positioned to adapt as both the science and regulatory environment continue to evolve.

If your practice offers or is considering peptide therapies and has questions about marketing, compliance, or regulatory risk, our healthcare attorneys at MDRXLaw are available to assist. You may contact us at 212.668.0200 or via email at info@mdrxlaw.com to discuss your specific questions.